These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19952960)

  • 1. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN.
    De Cesare M; Sfondrini L; Campiglio M; Sommariva M; Bianchi F; Perego P; van Rooijen N; Supino R; Rumio C; Zunino F; Pratesi G; Tagliabue E; Balsari A
    J Immunother; 2010 Jan; 33(1):8-15. PubMed ID: 19952960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy.
    De Cesare M; Calcaterra C; Pratesi G; Gatti L; Zunino F; Mènard S; Balsari A
    Clin Cancer Res; 2008 Sep; 14(17):5512-8. PubMed ID: 18765543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG oligodeoxynucleotide stimulates protective innate immunity against human renal cell carcinoma xenografted in nude mice.
    Zhou PJ; Ma BB; He W; Xu D; Wang XH
    J Immunother; 2011 Sep; 34(7):535-41. PubMed ID: 21760530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
    Pourgholami MH; Yan Cai Z; Lu Y; Wang L; Morris DL
    Clin Cancer Res; 2006 Mar; 12(6):1928-35. PubMed ID: 16551879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model.
    Hamzah J; Altin JG; Herringson T; Parish CR; Hämmerling GJ; O'Donoghue H; Ganss R
    J Immunol; 2009 Jul; 183(2):1091-8. PubMed ID: 19561111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N; Mukherjee S; Das L; Das PK
    Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile.
    Horton HM; Dorigo O; Hernandez P; Anderson D; Berek JS; Parker SE
    J Immunol; 1999 Dec; 163(12):6378-85. PubMed ID: 10586027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.
    Ballas ZK; Rasmussen WL; Krieg AM
    J Immunol; 1996 Sep; 157(5):1840-5. PubMed ID: 8757300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen.
    Auf G; Carpentier AF; Chen L; Le Clanche C; Delattre JY
    Clin Cancer Res; 2001 Nov; 7(11):3540-3. PubMed ID: 11705874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration.
    Heikenwalder M; Polymenidou M; Junt T; Sigurdson C; Wagner H; Akira S; Zinkernagel R; Aguzzi A
    Nat Med; 2004 Feb; 10(2):187-92. PubMed ID: 14745443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
    Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
    Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
    Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex.
    Kuramoto Y; Nishikawa M; Hyoudou K; Yamashita F; Hashida M
    J Control Release; 2006 Oct; 115(2):226-33. PubMed ID: 16996162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-gamma mediates suppression of erythropoiesis but not reduced red cell survival following CpG-ODN administration in vivo.
    Thawani N; Tam M; Chang KH; Stevenson MM
    Exp Hematol; 2006 Nov; 34(11):1451-61. PubMed ID: 17046564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
    Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific Th2-cell migration into lung.
    Ashino S; Wakita D; Zhang Y; Chamoto K; Kitamura H; Nishimura T
    Int Immunol; 2008 Feb; 20(2):259-66. PubMed ID: 18156622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.